AbbVie: Russia Operations Status & Business Impact
Also known as: Abbvie
LeaveRussia detail: Continue Operations
AbbVie is an American publicly traded biopharmaceutical company founded in 2013.
Decision trail
Decision date 19/03/2022 · Reference ↗
AbbVie has temporarily suspended operations for the aesthetics products in Russia and paused the start of new clinical studies. Other operations are continued. Revenue increased in 2024 vs 2023 by more than +50%.
Local stats (LeaveRussia)
Status history since 2022
- 03/08/2026 — operating · Imported from KSE LeaveRussia
Exposure profile
Get alerts if this company's Russia status changes
7-day Pro trial includes watchlists for companies you track. No credit card. Full exposure maps are on Professional after the trial.
Start 7-day Pro trialGeopolitical context and sanctions impact
AbbVie is a Pharma & Healthcare company based in USA. Current Russia status in our dataset is operating: continued operations in Russia remain a compliance, reputational and counterparties risk for EU and allied firms. Eastern Europe Impact translates those facts into business consequences — sanctions screening, supply-chain exposure and reconstruction-side opportunity — with transparent confidence labels rather than speculation.
Risk assessment and how to use this profile
Start with the status badge and decision trail, then check possible sanctions matches and recent events mentioning AbbVie. A 7-day Pro trial adds watchlists so you are notified if Russia status, designations or linked events change. Full exposure maps (energy, transport, commodities) are on Professional. This page is risk information, not legal or investment advice.
Questions about AbbVie
What kind of data does Eastern Europe Impact provide on AbbVie?
- Eastern Europe Impact publishes verified intelligence on AbbVie's Russia status: current operating posture, sources (including the KSE LeaveRussia project), status history since 2022, sanctions-list matches, and linked events. Each profile is risk information for compliance and due diligence — not legal advice.
How can Eastern Europe Impact data on AbbVie help my business?
- Use the AbbVie profile to check counterparties, suppliers and customers for Russia exposure, sanctions proximity and recent events before you contract, ship or invest. Watchlists alert you if the status or designations change.
How do we verify the information on AbbVie?
- We compile public reporting, company statements and the KSE LeaveRussia dataset, then label uncertainty. Status is not a legal determination — verify against primary filings and counsel before acting. Corrections go to corrections@easterneuropeimpact.com.
How much does Eastern Europe Impact cost?
- The company checker is free. A 7-day Pro trial (no credit card) unlocks live Daily Impact Briefs, full event profiles and watchlists. After the trial, Individual is €19/month; Professional and Business add exposure maps, sanctions entity pages and API access. See /pricing.